Wadhwa M S, Rice K G
College of Pharmacy, Ohio State University, Columbus 43210, USA.
J Drug Target. 1995;3(2):111-27. doi: 10.3109/10611869509059211.
Glycotargeting relies on carrier molecules possessing carbohydrates that are recognized and internalized by cell surface mammalian lectins. Numerous types of glycotargeting vehicles have been designed based on the covalent attachment of saccharides to proteins, polymers and other aglycones. These carriers have found their major applications in antiviral therapy, immunoactivation, enzyme replacement therapy and gene therapy. This review compared different types of glycotargeting agents and the lectins which have been successfully targeted to treat both model and human diseases. It may be concluded that the discovery of new mammalian lectins which endocytose their ligands will lead to the rapid development of new glycotargeting agents founded on the principles of carbohydrate-protein interactions.
糖靶向作用依赖于带有碳水化合物的载体分子,这些碳水化合物能被细胞表面的哺乳动物凝集素识别并内化。基于糖类与蛋白质、聚合物及其他苷元的共价连接,人们设计了多种类型的糖靶向载体。这些载体已在抗病毒治疗、免疫激活、酶替代疗法及基因治疗中得到了主要应用。本综述比较了不同类型的糖靶向剂以及已成功靶向用于治疗模型疾病和人类疾病的凝集素。可以得出结论,发现能内吞其配体的新哺乳动物凝集素将促使基于碳水化合物 - 蛋白质相互作用原理的新型糖靶向剂迅速发展。